ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer
Patterns of radiation usage in breast conserving therapy for women 70 years and older with stage I breast cancer are changing: more women are opting for radioactive implants and those with estrogen positive tumors are opting out of radiation therapy, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4. The abstract (#6094) received an ASCO Merit Award. In another abstract (#1037), the researchers report that women with estrogen negative tumors were 91 percent more likely to die from breast cancer if they did not receive radiation therapy after a lumpectomy.
Given the relatively recent developments in radiation therapy (i.e., an increased use of brachytherapy and external beams) and data supporting the idea that radiation isn't necessary for women with estrogen positive tumors, researchers wanted to see how actual practice patterns were impacted.
Researchers found that there was a modest increase in the percentage of women with estrogen receptor positive cancers who did not get radiation therapy starting around 2004, and increasing use of radioactive implants, such the MammoSite, Contura, Savi or similar devices, since 2002.
There was also a corresponding drop in women who received external beam radiation, according to Xinglei Shen, M.D., a resident in the Department of Radiation Oncology at Thomas Jefferson University Hospital. "Among women with estrogen receptor negative cancers, there was not the same increase in frequency of women who did not get radiation, but there was an increased use of radioactive implants," he said.
The consequence of those findings was determining what impact omitting radiation has on survival. While there is data that the omission of radiation therapy in women with estrogen receptor positive tumors who receive endocrine therapy, such as Tamoxifen, is not associated with a survival difference, limited data exists for estrogen receptor negative tumors in older women who undergo breast conservation.
"From the randomized trial data, we know that women with estrogen receptor positive stage I breast cancer have no detriment to survival by avoiding radiation, as long as they took Tamoxifen," Dr. Shen said. "However, it is unknown if this would be the case in women with estrogen receptor negative cancer."
Dr. Shen worked with Jefferson Medical College student Andrzej Wojcieszynski to examine survival in these women, and found that they were 91 percent more likely to die from breast cancer if they did not receive radiation therapy after a lumpectomy. (Abstract #1037).
"We have to be cautious when interpreting survival data from the SEER because of potential confounding variables, such as the health of the patients and use of chemotherapy," Dr. Shen said. "However, these data do raise hypotheses for future study."
"Our conclusion is that adjuvant radiation therapy after lumpectomy reduces breast cancer mortality in women over 70 with stage I, estrogen receptor negative breast cancers, and that radiation is currently underutilized in these women," said Wojcieszynski.
Source: Thomas Jefferson University
Articles on the same topic
- Breast cancer drug pushes colon cancer cells to their deathWed, 8 Jun 2011, 19:39:17 UTC
- Mayo Clinic, NCCTG find no tie between PTEN and response to breast cancer drugSun, 5 Jun 2011, 1:02:42 UTC
- Hormone deprivation therapy for prostate cancer may raise diabetes riskSat, 4 Jun 2011, 19:03:41 UTC
- Obesity raises breast cancer survivors' risk of dying of the cancerSat, 4 Jun 2011, 19:03:30 UTC
- Fetal programming of disease risk to next generation depends on parental genderSat, 4 Jun 2011, 19:03:21 UTC
- UB played major role in study on drug that reduces breast cancer in high-risk womenSat, 4 Jun 2011, 17:32:33 UTC
- Breast cancer surgery patients benefit from adding radiation therapySat, 4 Jun 2011, 16:02:44 UTC
- Silencing a deadly conversation in breast cancerThu, 2 Jun 2011, 14:39:46 UTC
Other sources
- Breast cancer drug pushes colon cancer cells to their deathfrom Science DailyWed, 8 Jun 2011, 19:30:31 UTC
- Breast cancer drug pushes colon cancer cells to their deathfrom PhysorgWed, 8 Jun 2011, 18:30:38 UTC
- Drug prevents some breast cancersfrom Sciencenews.orgTue, 7 Jun 2011, 15:40:09 UTC
- Drug prevents some breast cancersfrom Sciencenews.orgTue, 7 Jun 2011, 14:20:10 UTC
- Breast cancer drug with fewer side effects found to cut risk of tumorsfrom LA Times - HealthMon, 6 Jun 2011, 19:30:23 UTC
- Hormone test predicts ovarian function after chemotherapy for breast cancerfrom Science DailyMon, 6 Jun 2011, 17:30:39 UTC
- Drug prevents breast cancer in some women: studyfrom CBC: HealthSun, 5 Jun 2011, 1:00:13 UTC
- Breast cancer drug with fewer side effects found to cut risk of tumorsfrom LA Times - ScienceSun, 5 Jun 2011, 0:00:28 UTC
- Drug prevents breast cancer in some women: studyfrom CBC: Technology & ScienceSun, 5 Jun 2011, 0:00:18 UTC
- Breast cancer surgery patients benefit from adding radiation therapy, study suggestsfrom Science DailySat, 4 Jun 2011, 23:30:26 UTC
- Obesity raises breast cancer survivors' risk of dying of the cancer, study findsfrom Science DailySat, 4 Jun 2011, 23:30:21 UTC
- Exemestane reduces breast cancer in high-risk women, researchers showfrom Science DailySat, 4 Jun 2011, 23:30:19 UTC
- Breast cancer drug with fewer side effects found to cut risk of tumorsfrom LA Times - HealthSat, 4 Jun 2011, 20:00:15 UTC
- Obesity raises breast cancer survivors' risk of dying of the cancerfrom PhysorgSat, 4 Jun 2011, 19:00:23 UTC
- Hormone-blocking drug reduces breast cancer riskfrom PhysorgSat, 4 Jun 2011, 18:00:18 UTC
- Estrogen blocker cuts breast cancer risk 65%: studyfrom PhysorgSat, 4 Jun 2011, 18:00:16 UTC
- Breast cancer surgery patients benefit from adding radiation therapyfrom PhysorgSat, 4 Jun 2011, 17:30:20 UTC
- UB played major role in study on drug that reduces breast cancer in high-risk womenfrom PhysorgSat, 4 Jun 2011, 17:30:19 UTC
- Study confirms long-lasting anticancer benefit of zoledronic acid for women with early-stage breast cancerfrom PhysorgFri, 3 Jun 2011, 23:30:35 UTC
- No tie found between PTEN and response to breast cancer drug herceptin, according to new studyfrom Science DailyFri, 3 Jun 2011, 23:30:28 UTC
- Emerging trends in radiation therapy for women over 70 with early stage breast cancerfrom PhysorgThu, 2 Jun 2011, 21:30:36 UTC
- Emerging trends in radiation therapy for women over 70 with early stage breast cancerfrom Science DailyThu, 2 Jun 2011, 21:30:18 UTC
- Silencing a deadly conversation in breast cancerfrom Science DailyThu, 2 Jun 2011, 14:30:29 UTC
- ‘Hedgehog’ silencer halts cancerfrom Science AlertThu, 2 Jun 2011, 14:30:23 UTC
- Silencing a deadly conversation in breast cancerfrom PhysorgThu, 2 Jun 2011, 13:30:31 UTC